Arguably the biggest challenge in pediatric oral solid formulation development is to develop flexible dosage forms with measurable and easy to administer dosage, preferably formulated with taste-masking properties for better acceptance of the drug formulation in children. This Q&A session with formulation and bioavailability experts addresses formulation challenges for pediatric populations and how they are overcoming them.
ALK-Abelló is a global research-driven pharmaceutical company that focuses on the prevention, diagnosis, and treatment of allergies. By partnering with Catalent, ALK-Abelló was able to realize the first patient-friendly allergen immunotherapy and deliver on their promise of improving the quality of life for allergy patients.
Very few new molecular entities in active clinical development are readily bioavailable, and when dosed at escalated levels, even these may not be sufficiently absorbed. Learn how spray-dried amorphous dispersion might help.
With the Better Treatments by Design process, Catalent aims to achieve optimal outcomes for innovators, prescribers, and patients. By applying advanced dose design principles early, we can help you achieve optimal absorption profiles as well as improve patient adherence and compliance, leading to greater payer acceptance, more scripts, and potentially better patient outcomes.